Possible Alternative to IVIG Therapy Not Too Far Away
November 11, 2013; Posted by: webleed staff
NewsMedical interviewed Professor Richard Pleass, 2013 Universal Biotech Innovation Prize winner, about his development and idea to replace the costly IVIG Therapy.
Currently, intravenous immunoglobulin therapy or IVIG is used to treat all kinds of autimmune diseases ranging from anemia and lupus to ITP and Kawasaki disease. Today, IVIG is seen as costly with the dependence upon human plasma donation as a major inadequacy.
NewsMedical interviewed Professor Richard Pleass who was asked what winning the 2013 Universal Biotech Innovation Prize meant to him and his new biomimetic development: “It’s a huge vote of confidence in Hexagard™ and has raised awareness of the limitations and inadequacies of existing drugs…Now that we have the basic molecule we are keen to get HexaGard into patients who need it most.”
Professor Pleass goes on to list all of the key reasons why HexaGard has advantages over current IVIG drugs:
- Small
- Stable
- Safe
- Superior
- Serviceable
- Saleable
The next step for this alternative is funding so the drug can then make it to providers and patients.
